WILL VOELZKE, M.D.

Injection, fosnetupitant 235 mg and palonosetron 0.25 mg

Injection, pegfilgrastim-jmdb (fulphila), biosimilar, 0.5 mg

Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes

Administration of chemotherapy into vein, 1 hour or less

New patient office or other outpatient visit, 60-74 minutes

Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l

New patient office or other outpatient visit, 45-59 minutes

Established patient office or other outpatient visit, 40-54 minutes

Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes

Drawing of blood for a medical problem

Established patient office or other outpatient visit, 30-39 minutes

Administration of additional new drug or substance into vein, 1 hour or less

Administration of additional new drug or substance into vein using push technique

Injection, zoledronic acid, 1 mg

Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle

Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less

Established patient office or other outpatient visit, 20-29 minutes

Injection, rituximab-abbs, biosimilar, (truxima), 10 mg

Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes

Injection of drug or substance into vein

Infusion into a vein for hydration, 31-60 minutes

Injection, carboplatin, 50 mg

Administration of chemotherapy into vein, each additional hour

Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg

Injection, pembrolizumab, 1 mg

Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less

Injection, palonosetron hcl, 25 mcg

Irrigation of implanted venous access drug delivery device

Injection of drug or substance under skin or into muscle

Injection of additional new drug or substance into vein

Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion

Infusion into a vein for therapy, prevention, or diagnosis, each additional hour

Infusion into a vein for hydration, each additional hour

Injection, denosumab, 1 mg

Injection, fluorouracil, 500 mg

Injection, epoetin alfa, (for non-esrd use), 1000 units

Injection, granisetron hydrochloride, 100 mcg

Injection, leucovorin calcium, per 50 mg

Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg

Infusion, normal saline solution, sterile (500 ml = 1 unit)

Infusion, normal saline solution , 1000 cc

Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use)

Injection, magnesium sulfate, per 500 mg

Injection, paclitaxel, 1 mg

Injection, dexamethasone sodium phosphate, 1 mg